retatrutide phase 2 trial new england journal of medicine approval: FDA status, clinical results, and when it could be available Retatrutide Phase 3: 60% Achieved

Second, we did not assess adherence to medication in the sample

14 Le says these challenges raise health equity questions

Qualifying comorbidities include type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and established cardiovascular disease

For once-weekly injections, administer the missed dose as soon as possible if within the specified timeframe (e.g., within 5 days for semaglutide, at least 3 days before the next dose for dulaglutide)

By contrast, countries like India, which do not award patent term extensions, could see generic competition entering much sooner once the patents on the main compound expire there in 2026

L., Murphy, K